Pluri (PLUR) Competitors $5.51 -0.05 (-0.90%) Closing price 03:42 PM EasternExtended Trading$5.68 +0.17 (+3.10%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. ACRS, NVCT, NLTX, MOLN, TIL, BIOA, CGEN, ALEC, GALT, and ACOGShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Aclaris Therapeutics (ACRS), Nuvectis Pharma (NVCT), Neoleukin Therapeutics (NLTX), Molecular Partners (MOLN), Instil Bio (TIL), BioAge Labs (BIOA), Compugen (CGEN), Alector (ALEC), Galectin Therapeutics (GALT), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Aclaris Therapeutics Nuvectis Pharma Neoleukin Therapeutics Molecular Partners Instil Bio BioAge Labs Compugen Alector Galectin Therapeutics Alpha Cognition Pluri (NASDAQ:PLUR) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment. Which has better earnings and valuation, PLUR or ACRS? Pluri has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$330K130.74-$20.89M-$5.53-1.00Aclaris Therapeutics$18.72M8.91-$132.07M-$1.39-1.11 Does the media prefer PLUR or ACRS? In the previous week, Pluri had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 3 mentions for Pluri and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.77 beat Pluri's score of 0.64 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, PLUR or ACRS? Pluri has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Do insiders and institutionals believe in PLUR or ACRS? 16.6% of Pluri shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 25.9% of Pluri shares are held by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is PLUR or ACRS more profitable? Aclaris Therapeutics has a net margin of -732.42% compared to Pluri's net margin of -2,563.29%. Aclaris Therapeutics' return on equity of -30.73% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-2,563.29% -4,191.91% -85.40% Aclaris Therapeutics -732.42%-30.73%-22.74% Do analysts rate PLUR or ACRS? Pluri presently has a consensus price target of $12.00, indicating a potential upside of 117.79%. Aclaris Therapeutics has a consensus price target of $9.71, indicating a potential upside of 530.80%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aclaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 SummaryAclaris Therapeutics beats Pluri on 11 of the 17 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.55M$2.90B$5.50B$8.96BDividend YieldN/A2.44%5.25%4.02%P/E Ratio-1.007.8219.9019.84Price / Sales130.74295.68436.90127.27Price / CashN/A41.8337.0657.97Price / Book5.517.868.125.62Net Income-$20.89M-$54.95M$3.16B$248.50M7 Day Performance2.23%6.24%4.40%5.54%1 Month Performance25.51%5.70%4.09%7.52%1 Year Performance-5.00%8.08%34.53%22.06% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri3.3433 of 5 stars$5.51-0.9%$12.00+117.8%-3.8%$43.55M$330K-1.00150News CoverageGap DownACRSAclaris Therapeutics2.6211 of 5 stars$1.42-3.4%$9.71+584.1%+14.2%$159.17M$18.72M-1.02100NVCTNuvectis Pharma3.2535 of 5 stars$7.47-1.1%$17.00+127.6%+19.0%$157.75MN/A-6.618News CoveragePositive NewsNLTXNeoleukin TherapeuticsN/A$16.16-2.5%N/A-47.0%$151.87MN/A-5.2090High Trading VolumeMOLNMolecular Partners2.7956 of 5 stars$3.79+0.8%$12.00+216.6%-44.8%$151.81M$5.65M-1.97180TILInstil Bio3.1138 of 5 stars$20.83-9.3%$119.00+471.3%+130.6%$150.66MN/A-1.74410Positive NewsBIOABioAge LabsN/A$4.13-1.7%N/AN/A$150.57MN/A0.00N/ANews CoverageCGENCompugen1.5404 of 5 stars$1.78+7.2%$4.00+124.7%-0.6%$148.13M$27.86M-11.1370Positive NewsALECAlector4.0507 of 5 stars$1.40-5.4%$4.00+185.7%-67.0%$147.99M$100.56M-1.11270News CoverageGALTGalectin Therapeutics1.0999 of 5 stars$2.11-9.4%$6.00+184.4%-4.6%$147.47MN/A-2.939Positive NewsACOGAlpha Cognition1.698 of 5 stars$9.33+2.5%$20.00+114.4%N/A$145.86MN/A-7.77N/A Related Companies and Tools Related Companies Aclaris Therapeutics Competitors Nuvectis Pharma Competitors Neoleukin Therapeutics Competitors Molecular Partners Competitors Instil Bio Competitors BioAge Labs Competitors Compugen Competitors Alector Competitors Galectin Therapeutics Competitors Alpha Cognition Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLUR Stock Alerts